Inovio's '3-Hour' COVID Cure Claims Spark Derivative Suit
The top brass at biopharmaceutical company Inovio Pharmaceuticals Inc. was hit Monday with a shareholders' derivative action in Pennsylvania federal court accusing the firm's leadership of preying on investors by claiming...To view the full article, register now.
Already a subscriber? Click here to view full article